Mental Health Care - North Chicago, Illinois, United States
NeuroLucent is an early-stage company focused on developing small-molecule therapeutics to treat the cognitive loss associated with Alzheimer's disease. We are targeting Ca2+ dysregulation, an established hallmark of AD neurons. The NeuroLucent team has uncovered a key intracellular Ca2+ channel that is over-expressed and hyperactive in AD neurons. Preclinical validation has been achieved through the identification of compounds that normalize Ca2+ levels and decrease disease markers in animal models. NeuroLucent is currently focused on identifying a clinical candidate.
1&1 Email Provider